Neurocrine biosciences, inc. announces it will present data analyses evaluating the long-term effects of once-daily 40 mg ingrezza

Neurocrine biosciences, inc. announced it will present data analyses evaluating the long-term effects of once-daily 40 mg ingrezza® (valbenazine) in adults with tardive dyskinesia (td), an involuntary movement disorder. a data analysis will also be presented on the long-term effects of ingrezza in patients who demonstrated improvement in td symptoms as early as two weeks. in addition, neurocrine biosciences will present data on the impact possible td has on a patient's health-related quality of life from re-kinect. these data will be presented at the 2019 annual psych congress in san diego, oct. 3-6, 2019.
NBIX Ratings Summary
NBIX Quant Ranking